Baseline characteristics of 50 patients
Characteristic . | Value . |
|---|---|
| Age, y, median (range) | 71.5 (65-78) |
| Older than 70 y, no. (%) | 32 (64) |
| Older than 75 y, no. (%) | 7 (14) |
| Sex, no. (%) | |
| Male | 29 (58) |
| Female | 21 (42) |
| Immunoglobulin heavy chain type, no. (%) | |
| IgG | 30 (60) |
| IgA | 11 (22) |
| Light chain only | 7 (14) |
| Nonsecretory | 2 (4) |
| Unfavorable/assessable cytogenetic, no. (%) | 7/29 (24) |
| Durie-Salmon stage, no. (%) | |
| I | 9 (18) |
| II | 2 (4) |
| III | 39 (78) |
| ISS stage, no. (%) | |
| I | 13 (26) |
| II | 23 (46) |
| III | 14 (28) |
| WHO performance status at least 1, no. (%) | 10 (20) |
| Serum β2-microglobulin level at least 3.5 mg/L, no. (%) | 30 (60) |
| Serum albumin level less than 3.5 g/dL, no. (%) | 20 (40) |
| Serum creatinine level greater than 2 mg/dL, no. (%) | 7 (14) |
| Hemoglobin level below 11.5 g/dL, no. (%) | 24 (48) |
| Platelet count below 130 × 109/L, no. (%) | 8 (16) |
Characteristic . | Value . |
|---|---|
| Age, y, median (range) | 71.5 (65-78) |
| Older than 70 y, no. (%) | 32 (64) |
| Older than 75 y, no. (%) | 7 (14) |
| Sex, no. (%) | |
| Male | 29 (58) |
| Female | 21 (42) |
| Immunoglobulin heavy chain type, no. (%) | |
| IgG | 30 (60) |
| IgA | 11 (22) |
| Light chain only | 7 (14) |
| Nonsecretory | 2 (4) |
| Unfavorable/assessable cytogenetic, no. (%) | 7/29 (24) |
| Durie-Salmon stage, no. (%) | |
| I | 9 (18) |
| II | 2 (4) |
| III | 39 (78) |
| ISS stage, no. (%) | |
| I | 13 (26) |
| II | 23 (46) |
| III | 14 (28) |
| WHO performance status at least 1, no. (%) | 10 (20) |
| Serum β2-microglobulin level at least 3.5 mg/L, no. (%) | 30 (60) |
| Serum albumin level less than 3.5 g/dL, no. (%) | 20 (40) |
| Serum creatinine level greater than 2 mg/dL, no. (%) | 7 (14) |
| Hemoglobin level below 11.5 g/dL, no. (%) | 24 (48) |
| Platelet count below 130 × 109/L, no. (%) | 8 (16) |
ISS indicates International Staging System.
Conversion units: β2-microglobulin, 1 mg/L = 84.75 nM/L; creatinine, 1 mg/dL = 88.4 μM/L.